None listed
Conditions
Interventions
Dietary Supplement : Participants were randomly assigned to one of the following two groups and orally administered the investigational product once daily for 8 weeks.
VC1702 group: 500 mg/day, once
Sponsors
Univera
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adults aged 19 years or older at the time of screening (male or female) 2) Individuals with a Global Index Score (GIS) of 30 to 50 on the Chronic Venous Insufficiency Questionnaire (CIVIQ-20) 3) Individuals who voluntarily agreed to participate and provided written informed consent after receiving a full explanation of the study and demonstrating adequate understanding, and who are willing to comply with study requirements and precautions
Exclusion criteria
Exclusion criteria: 1) Individuals who have undergone surgery or received pharmacological treatment for venous disease within 8 weeks prior to study participation 2) Individuals who have received external compression therapy within 4 weeks prior to study participation 3) Individuals with a BMI = 30 kg/m^2 4) Individuals who have taken medications or health functional foods that may affect venous circulation within 8 weeks prior to study participation 5) Women currently receiving hormone replacement therapy 6) Individuals who have undergone procedures, surgery, or received pharmacological treatment related to lumbar spine disorders 7) Individuals with any of the following diseases requiring treatment or with a relevant medical history: Heart failure, myocardial infarction, cerebrovascular disease, atherosclerosis, diabetes mellitus, thyroid disorders, gastric ulcer, gastrointestinal bleeding, infectious diseases, systemic inflammatory diseases, acute inflammation, malignant tumors, renal disease, renal dysfunction, liver disease, or uncontrolled hypertension 8) Individuals with known hypersensitivity to the investigational product, placebo, or any of their ingredients 9) Individuals who have participated in another clinical trial within 8 weeks prior to study participation 10) Pregnant or breastfeeding women 11) Individuals deemed unsuitable for participation by the investigator based on clinical laboratory test results or other reasons, including: -AST or ALT > 2 × the upper limit of normal -Creatinine > 2 × the upper limit of normal -Any other clinically significant abnormal laboratory findings
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Calf circumference;Calf volume;CIVIQ-20 | — |
Secondary
| Measure | Time frame |
|---|---|
| Calf skin thickness;Blood flow velocity and vessel diameter;Blood flow volume;kin surface temperature of the leg;Blood inflammatory markers (hs-CRP, ESR) | — |
Countries
Korea, Republic of
Contacts
Public ContactEUN-SOO JUNG
Jeonbuk National University Hospital
Outcome results
None listed